# Post-menopausal Women Osteoporosis(Phase III)

> **NCT01806792** · PHASE3 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 150 (actual)

## Conditions studied

- Postmenopausal Women Osteoporosis

## Interventions

- **DRUG:** risedronate combine
- **DRUG:** Risedronate
- **DRUG:** Placebo(for Risedronate)
- **DRUG:** Placebo(for risedronate combine)

## Key facts

- **NCT ID:** NCT01806792
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-08
- **Final completion:** 2011-03
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2013-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01806792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01806792, "Post-menopausal Women Osteoporosis(Phase III)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01806792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*